AnPac Bio (ANPC) stock is soaring. A biopharma stock to buy?

2 min read | June 19, 2021 01:49 AM AEST | By Raza Naqvi

AnPac Bio (ANPC) stock is soaring. A biopharma stock to buy? — Image source: A_stockphoto,Shutterstock

AnPac (NASDAQ:ANPC, ANPC:US) stock & financial performance

In the first quarter of 2021, AnPac's total revenue stood at RMB 2.2 million, which reflected an increase of 137.2 per cent year-over-year (YoY). Its gross profit margin climbed to 58.4 per cent in Q1 2021, up by 25.7 per cent from Q1 2020.

AnPac Bio also achieved a record high number of commercial Cancer Differential Analysis (CDA) tests in Q1 2021. The average selling price of these CDA tests was RMB 401 in the first quarter, up five per cent YoY.

The biopharmaceutical company recorded a net loss of RMB 29.3 million in Q1 2021, as compared to a net loss of RMB 21.2 million in Q1 2020. At the end of the first quarter ending March 31, 2021, the company's cash and cash equivalents were RMB 9 million, up from RMB 3 million in the fourth quarter of 2020.

ANPC stock grew by eight per cent in the last nine months and soared by 16 per cent in the past month. Compared to its 52-week high of US$ 12.09 apiece, recorded on March 9, 2021, and the current discounted price could be used as an entry point.
The above constitutes a preliminary view and any interest in stocks should be evaluated further from an investment point of view.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.